There were 63 cases of adverse reactions of Slimming Injections reported this year / 39 cases were reported for weight loss purposes, more than 60%. Most of the symptoms were gastrointestinal diseases.

Incretin drugs, commonly known as "slimming shots", are important drugs for diabetic patients to control blood sugar. At the same time, they are regarded by many people as a weight loss savior because they regulate appetite and delay gastric emptying. However, as the number of users increases, the side effects of slimming injections have also attracted attention. According to statistics from the Food and Drug Administration, 63 cases of suspected adverse reactions to the use of GLP-1 receptor agonist drugs have been received this year, of which more than 60% were used for weight loss. The majority of reported symptoms were gastrointestinal diseases.

"Slimming injection" is a popular name for injectable drugs for weight loss and blood sugar control. In recent years, most of them refer to incretin-related drugs such as GLP-1 receptor agonists and GLP-1/GIP receptor agonists. These drugs can simulate the effects of human hormones and produce effects such as suppressing appetite and helping blood sugar control. They were originally used as diabetes treatment drugs, but in recent years they have also been used for weight management.

Liu Jiaping, the Drug Group of the Food and Drug Administration, said that among the adverse reaction notifications related to GLP-1 receptor agonist drugs received by the National Adverse Drug Reaction Notification System this year, 39 were for weight loss and 24 were for diabetes treatment. The reported symptoms include gastrointestinal diseases (including abdominal pain, intestinal obstruction, pancreatitis), hypoglycemia, nausea, vomiting, discomfort at the injection site, etc.

Due to the increase in the number of users of Slimming Injections, and the expansion of users from diabetes to the general public, the Food and Drug Administration has required pharmaceutical manufacturers to provide patient medication safety guidelines, outlining possible risks such as acute kidney injury and optic neuropathy. Liu Jiaping also mentioned that the Food and Drug Administration has written to manufacturers to submit a post-marketing safety study (PASS) plan and formulate a risk assessment and management plan (RMP), and continues to monitor domestic and foreign drug safety information, collect and compile relevant data for evaluation, and adopt corresponding risk management and control measures for new drug risks.

The Food and Drug Administration reminds that GLP-1 receptor agonist injections are prescribed by doctors. People should use them according to the prescription and instructions after medical examination and professional evaluation. They should not buy them through informal channels or inject them on their own to avoid endangering health due to improper use or unknown sources of drugs. If an adverse drug reaction occurs during medication, medical assistance should be sought immediately. If medical personnel or patients suspect that an adverse reaction is caused by the use of drugs, please report it to the National Adverse Drug Reaction Reporting Center immediately.